FMS-RELATED GENES IN OVARIAN AND ENDOMETRIAL NEOPLASIA

我们已经组装了专门固定和/或冷冻的卵巢和 子宫内膜癌，并已确定，通过定量检测 原位杂交分析、转录本表达 与FMS相关的探测器的补充与 这两种妇科疾病患者的攻击性临床行为 恶性肿瘤。我们建议进一步扩大这些调查范围。 为了更好地描述这些癌基因和其他癌基因在肿瘤中的作用 临床侵袭性卵巢和子宫内膜的发生 肿瘤的分子生物学和细胞学特征 FMS互补转录本的生理学及FMS相关 我们临床资料中的生长因子受体蛋白产物 在卵巢癌来源的培养细胞系中，因为这 基因产物似乎在卵巢和卵巢疾病中发挥重要作用 子宫内膜癌的发生，并可能成为潜在的靶点 “癌基因特异性”的药理学干预。

We have assembled specially-fixed and/or frozen ovarian and endometrial carcinomas and have established, by quantitative in situ hybridization analyses, that expression of a transcript complementary to a fms-related probe correlates strongly with aggressive clinical behavior in these two gynecologic malignancies. We propose to extend these investigations further to better characterize the role of these and other oncogenes in the genesis of clinically aggressive ovarian and endometrial neoplasms and to characterize the molecular biology and cellular physiology of the fms-complementary transcript and fms-related growth factor receptor protein product in our clinical material and in ovarian carcinoma-derived cultured cell lines, since this gene product appears to play an important role in ovarian and endometrial carcinogenesis and may be a potential target for "oncogene-specific" pharmacologic interventions.